Cidara Therapeutics (CDTX) announced updates to its planned Phase 3 registrational trial of CD388 following its End-of-Phase 2, EOP2, meeting with the U.S. Food and Drug Administration, FDA. Cidara is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback